News

The facility forms a key component of the company’s $23bn US investment programme, first outlined in April 2025, and aims to enhance the supply of RLT cancer treatments

Under the agreement, MediLink will receive upfront and near-term milestone payments totalling $570m. Additional development, regulatory, and commercial milestone payments are included in the deal, along with tiered

Through this partnership, Takeda aims to enhance patient care while exploring new opportunities for vedolizumab. Marketed as Entyvio, vedolizumab is approved for adults with moderately to severely active

Agamree is a new drug that operates by attaching to the same receptor as glucocorticoids while altering its downstream activity. The agreement involves the development, manufacturing and commercialisation

The approval offers healthcare providers with an additional option alongside the existing 1g version. The new kit contains 100ml Water for Infusion (WFI) and includes the nextaro reconstitution

The tender offer expired on 5 January 2026. The transaction involved purchasing all outstanding shares of Mersana at $25 per share in cash, along with one non-tradable contingent

The condition has an estimated prevalence of 25,000 patients in the US and an annual incidence of one to three new cases per 100,000 people. CK0804 is an

The approval applies to patients whose disease is metastatic or locally advanced, or where surgery may cause morbidity, and who have progressed on prior therapies or lack satisfactory

The first-in-class, subcutaneously administered hepcidin mimetic peptide, rusfertide is intended to regulate iron homeostasis and red blood cell production to help manage haematocrit levels in PV patients. The